Helicos BioSciences Corporation Announces Prenatal Diagnostics IP Sale To Sequenom
Helicos BioSciences Corporation (OTCQB: HLCS.PK) announced today that it has entered into an Asset Purchase Agreement with Sequenom, Inc. pursuant to which Sequenom purchased all rights, title and interest in Helicos’ United States Patent Application Serial Nos. 12/709,057 and 12/727,824 (Methods for Detecting Fetal Nucleic Acids and Diagnosing Fetal Abnormalities) and certain related proprietary materials. In consideration for the sale and transfer of the purchased assets, Sequenom paid Helicos $1.3 million.
"The transaction with Sequenom is consistent with our strategy for realizing the maximum value from Helicos’s foundational intellectual property portfolio,” stated Dr. Ivan Trifunovich, President and CEO of Helicos. “The two patent applications are intellectual property assets focused on the sequencing applications in prenatal molecular diagnostics (MDx), where Sequenom is a market leader, and where Helicos does not compete. The Helicos patent estate continues to dominate several aspects of the next-generation sequencing field, and the company intends to continue vigorously defending its IP rights through licensing and patent enforcement strategies, including the ongoing lawsuit against Illumina, Life Technologies, and Pacific Biosciences.”
Helicos will use the proceeds from the sale of assets to fund its ongoing operations.
Additional information can be found in Helicos’ Current Report on Form 8-K as filed with the SEC on April 10, 2012. This report includes a discussion regarding the company's need to raise capital.Forward-Looking Statements This press release contains "forward-looking statements". In particular, the statements herein regarding our litigation plans, ability to raise capital or finance our operations and statements preceded by, followed by or that include the words "intends", "estimates", "plans", "believes", "expects", "anticipates", "should", "could" or similar expressions, are forward-looking statements. Forward-looking statements reflect our current expectations and are inherently uncertain. Our actual results may differ significantly from our expectations. We assume no obligation to update this forward-looking information. A discussion of the risk factors facing us can be found under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2011, and in our other reports and filings with the Securities and Exchange Commission.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV